EP1951914A4 - Méthodes et agents diagnostiques et thérapeutiques - Google Patents

Méthodes et agents diagnostiques et thérapeutiques

Info

Publication number
EP1951914A4
EP1951914A4 EP06837256A EP06837256A EP1951914A4 EP 1951914 A4 EP1951914 A4 EP 1951914A4 EP 06837256 A EP06837256 A EP 06837256A EP 06837256 A EP06837256 A EP 06837256A EP 1951914 A4 EP1951914 A4 EP 1951914A4
Authority
EP
European Patent Office
Prior art keywords
diagnostic
agents
therapeutic methods
therapeutic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06837256A
Other languages
German (de)
English (en)
Other versions
EP1951914A2 (fr
Inventor
George Ka-Kit Lau
Chee-Kin Hui
Hai Ying Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENG SI YUAN (CHINA-INTERNATIONAL) HEPATITIS RESEARCH FOUNDATION
CHENG SI YUAN CHINA INTERNATIO
LAU GEORGE KA KIT
Original Assignee
CHENG SI YUAN (CHINA-INTERNATIONAL) HEPATITIS RESEARCH FOUNDATION
CHENG SI YUAN CHINA INTERNATIO
LAU GEORGE KA KIT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHENG SI YUAN (CHINA-INTERNATIONAL) HEPATITIS RESEARCH FOUNDATION, CHENG SI YUAN CHINA INTERNATIO, LAU GEORGE KA KIT filed Critical CHENG SI YUAN (CHINA-INTERNATIONAL) HEPATITIS RESEARCH FOUNDATION
Publication of EP1951914A2 publication Critical patent/EP1951914A2/fr
Publication of EP1951914A4 publication Critical patent/EP1951914A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP06837256A 2005-11-09 2006-11-09 Méthodes et agents diagnostiques et thérapeutiques Withdrawn EP1951914A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73548005P 2005-11-09 2005-11-09
PCT/US2006/043665 WO2007056527A2 (fr) 2005-11-09 2006-11-09 Methodes et agents diagnostiques et therapeutiques

Publications (2)

Publication Number Publication Date
EP1951914A2 EP1951914A2 (fr) 2008-08-06
EP1951914A4 true EP1951914A4 (fr) 2009-11-04

Family

ID=38023993

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06837256A Withdrawn EP1951914A4 (fr) 2005-11-09 2006-11-09 Méthodes et agents diagnostiques et thérapeutiques

Country Status (3)

Country Link
EP (1) EP1951914A4 (fr)
AU (1) AU2006311462A1 (fr)
WO (1) WO2007056527A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101979557B (zh) * 2010-10-28 2015-07-01 百奥迈科生物技术有限公司 一种siRNA分子及其在抗病毒药物中的应用
CN107427514B (zh) 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CN108802383B (zh) * 2018-06-21 2021-05-11 首都医科大学附属北京地坛医院 乙肝小三阳低复制期孕产期再激活监控设备

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043572A2 (fr) * 2001-11-16 2003-05-30 3M Innovative Properties Company Procedes et compositions lies a des composes irm et a des voies de recepteurs de type toll (tlr)
WO2005020912A2 (fr) * 2003-08-25 2005-03-10 3M Innovative Properties Company Administration de composes modificateurs de la reponse immunitaire
WO2005025583A2 (fr) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Administration de ligands tlr7 et de leurs prodrogues pour traiter l'infection au virus de l'hepatite c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043572A2 (fr) * 2001-11-16 2003-05-30 3M Innovative Properties Company Procedes et compositions lies a des composes irm et a des voies de recepteurs de type toll (tlr)
WO2005020912A2 (fr) * 2003-08-25 2005-03-10 3M Innovative Properties Company Administration de composes modificateurs de la reponse immunitaire
WO2005025583A2 (fr) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Administration de ligands tlr7 et de leurs prodrogues pour traiter l'infection au virus de l'hepatite c

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAVIES S L ET AL: "Isatoribine - Anti-hepatitis C virus drug TLR7 receptor agonist", DRUGS OF THE FUTURE, vol. 30, no. 9, September 2005 (2005-09-01), pages 886 - 891, XP002547239, ISSN: 0377-8282 *
HEMMI H ET AL: "SMALL ANTI-VIRAL COMPOUNDS ACTIVATE IMMUNE CELLLS VIA THE TLR7 MYD88-DEPENDENT SIGNALING PATHWAY", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 3, no. 2, 1 February 2002 (2002-02-01), pages 196 - 200, XP009000917, ISSN: 1529-2908 *
HORSMANS YVES ET AL: "Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection", HEPATOLOGY, vol. 42, no. 3, September 2005 (2005-09-01), pages 724 - 731, XP002547240, ISSN: 0270-9139 *
HUI CHEE-KIN ET AL: "Upregulation of toll-like receptor 7 is essential for serological clearance of hepatitis B surface antigen in chronic hepatitis B virus (HBV) infection", HEPATOLOGY, vol. 42, no. 4, Suppl. 1, October 2005 (2005-10-01), 56TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; SAN FRANCISCO, CA, USA; NOVEMBER 11 -15, 2005, pages 707A - 708A, XP002547237, ISSN: 0270-9139 *
ISOGAWA MASANORI ET AL: "Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.", JOURNAL OF VIROLOGY JUN 2005, vol. 79, no. 11, June 2005 (2005-06-01), pages 7269 - 7272, XP002547238, ISSN: 0022-538X *
LEE ET AL: "Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 11, 27 May 2003 (2003-05-27), pages 6646 - 6651, XP002307483, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1951914A2 (fr) 2008-08-06
WO2007056527A3 (fr) 2009-05-14
AU2006311462A1 (en) 2007-05-18
WO2007056527A2 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
EP1874800A4 (fr) Agents diagnostiques et thérapeutiques
EP1758605A4 (fr) Prouroguanyline servant d'agents therapeutiques ou diagnostiques
IL186616A (en) Spyro-oxa-indoles and their use as drugs
EP1962961A4 (fr) Demi-corps : agents thérapeutiques activés par dimérisation
GB0506147D0 (en) Therapeutic agents
GB0521139D0 (en) Therapeutic agent
EP1781685A4 (fr) Agents therapeutiques et diagnostiques
GB0516091D0 (en) Therapeutic agent
IL191072A0 (en) Therapeutic compositions and methods
GB0519797D0 (en) Therapeutic agents
EP1825005A4 (fr) Agents diagnostiques et therapeutiques a base de mer
GB0505437D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
GB0519350D0 (en) Therapeutic agents
GB0518819D0 (en) Therapeutic agents
GB0518817D0 (en) Therapeutic agents
GB0516661D0 (en) Therapeutic agents
GB0514738D0 (en) Therapeutic agents
EP1951914A4 (fr) Méthodes et agents diagnostiques et thérapeutiques
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0512726D0 (en) Multiple sclerosis therapy and diagnosis
GB0523998D0 (en) Therapeutic agents
GB0508153D0 (en) Therapeutic agent
GB0522433D0 (en) Therapeutic agents
GB0605738D0 (en) Novel diagnostic and therapeutic methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080605

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHANG, HAI YING,THE UNIVERSITY OF HONG KONG

Inventor name: HUI, CHEE-KIN,THE UNIVERSITY OF HONG KONG

Inventor name: LAU, GEORGE KA-KIT,THE UNIVERSITY OF HONG KONG

R17D Deferred search report published (corrected)

Effective date: 20090514

A4 Supplementary search report drawn up and despatched

Effective date: 20091005

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20090925BHEP

Ipc: C12Q 1/70 20060101AFI20070720BHEP

17Q First examination report despatched

Effective date: 20100120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100602